Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “In the third quarter we continued to advance the development programs of NXP800 and NXP900. The NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian carcinoma, a disease of unmet medical need, continues and we expect to report preliminary data from the study in 1Q 2024. In addition, the Food and Drug Administration granted NXP800 Orphan Drug Designation for the treatment of Cholangiocarcinoma, another deadly disease of unmet need.” Mr. Bentsur continued, “For NXP900, we initiated the dose escalation part of our Phase 1 study in patients with advanced solid tumors and published additional preclinical data highlighting the potential of NXP900 to treat tumors of squamous cell origin, including those with HIPPO pathway mutations.” Mr. Bentsur concluded, “Finally, we continue to be judicious with our financial resources and ended the quarter with approximately $22.1 million, which we expect will allow us to meet important milestones for both clinical programs and provide working capital into 1H 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVCT:
- Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
- Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
- Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
- Nuvectis Pharma announces initiation of NXP9000 Phase 1a trial